Sold as Kinevac, Sincalide. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Sincalide (sold as Kinevac, Sincalide), first approved Jul 21, 1976, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Kinevac | Part B | $396K | -6% | 3,021 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTSPostural Orthostatic Tachycardia Syndrome (POTS), Healthy · University of Copenhagen | Not applicable | Recruiting | Jun 13, 2025 |
| Jul 21, 1976 | KinevacNDA 17697 · New molecular entity | Bracco | 21 | Marketed |
| Nov 22, 2022 | SincalideNDA 210850 · New formulation or manufacturer | Maia Pharms Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
